Search

The crystal structure of the thiosemicarbazide derivative 4-cyclohexyl-1-(thiophene-2-carbonyl)thiosemicarbazide (ChtcTSC), C12H17N3OS2, is reported here. The title compound ChtcTSC has been characterized by various physicochemical techniques viz UV–Vis., Infrared, and NMR. It crystallizes in the monoclinic system having space group P21/c. The dihedral angle between the thiophene and cyclohexyl rings is 60.7(4)°. The crystal packing is established by intermolecular N–H⋯O packing interactions involving a three-center donor hydrogen bond between the keto oxygen atom of the thiophene group and H atoms belonging to the hydrazine group which links the molecules into chains along the (011) plane of the unit cell. Hydrogen bonds between the hydrazine hydrogen atom and one of the thiophene groups and C–H⋯Cg π -ring interactions provide added stability to the crystal packing. The fingerprint plots associated with Hirshfeld surface analysis indicate that there are different types of weak interactions viz. O⋯H–C, O⋯H–N, and S⋯H–C. The geometry optimization has been performed using the DFT method, and geometrical parameters thus obtained for ChtcTSC correlate with the single-crystal X-ray data. The TD-DFT study showed a small HOMO and LUMO energy gap of 2.869 eV. The electronic transition from the ground state to the excited state due to a transfer of electrons from HOMO to LUMO levels is mainly associated with the n → π* transition. The crystal structure of 4-cyclohexyl-1-(thiophene-2-carbonyl)thiosemicarbazide (ChtcTSC) is reported here where the title compound ChtcTSC has been characterized by various physiochemical techniques including UV–Vis., Infrared, NMR, DFT and Hirshfeld surface analysis. [ABSTRACT FROM AUTHOR]

• Crystal structure of N-phenyl-5-(pyridin-3-yl)−1,3,4-oxadiazol-2-amine (Pypao). • Mn(II) catalyzed cyclization of hydrazine carbothioamide to oxadiazole. • Hirshfeld surface analysis, DFT and TD-DFT analysis of Pypao. • Molecular docking of Pypao with oncoproteins of HPV. • Anticancer activity of Pypao against cervical cancer (SiHa) cells. The global burden of cervical cancer is continuously increasing day by day affecting the world population. Wide arrays of agents are prevalent for the treatment of this chronic disease but the survival rates are still limited. The titled compound N-phenyl-5-(pyridin-3-yl)-1,3,4-oxadiazol-2-amine (Pypao) was prepared through the cyclization of nicotinoyl-N-phenyl hydrazine carbothioamide catalyzed by manganese (II) acetate. Uv-Vis, IR, NMR, elemental analyses, and single-crystal X-ray data were utilized for the description of the compound Pypao. The crystal structure of Pypao is stabilized via intermolecular hydrogen bonding interactions, which is further confirmed with Hirshfeld surface analysis. The DFT methods were also used to optimize the Pypao and obtained bond parameters have been found coherent with the experimental data. FMO and TD-DFT studies are also performed to gain insights into the electronic behavior of Pypao. Furthermore, the binding potential of Pypao to different oncoproteins of HPV namely E6, E6AP, and E7 have been examined through a molecular docking study. The in-vitro anticancer activity of Pypao has been investigated against SiHa cells. The anticancer potential of Pypao has been evaluated through various assays including MTT, DAPI stating, AO/PI staining, etc. Both time and dose-dependent activity of Pypao have been investigated. [Display omitted] [ABSTRACT FROM AUTHOR]

• Synthesis of 2-(4-methoxyphenyl)−5-(2-pyridyl)−1,3,4-thiadiazole (Mppth). • Crystal structure of Mppth is stabilized by H-bonding and π−π stacking interaction. • Zn(II) catalyzed cyclization of thiohydrazide to thiadiazole. • DFT and Hirshfeld surface analysis of Mppth is performed. • Molecular docking of Mppth with CYP-19, JAK2, BCL-2 & caspase3 receptors. A new compound 2-(4-methoxyphenyl)-5-(2-pyridyl)-1,3,4-thiadiazole (Mppth) has been synthesized and characterized with the aid of IR, NMR, and single-crystal X-ray diffraction techniques. During the reaction, the substituted thiohydrazide got cyclized into the corresponding thiadiazole (Mppth) in the presence of zinc(II) nitrate via loss of H 2 O. The Mppth crystallizes in an orthorhombic system with space group P 21 21 21. The solid-state structure of Mppth is stabilized via intermolecular hydrogen bonding and π-π interaction between phenyl rings. The intermolecular interactions present in the crystal structure of Mppth are also confirmed with Hirshfeld surface analysis. The geometry optimization has been performed using the DFT method and geometrical parameters thus obtained for the Mppth correlate with the single-crystal X-ray data. The FMO analysis shows a small HOMO and LUMO energy gap of 5.48 eV for Mppth suggesting its potential application as NLO material. The electronic transition from the ground state to the excited state due to a transfer of electrons from the HOMO to LUMO levels is mainly associated with the π→π* transition. Molecular docking studies are also performed against CYP-19 (PDB: 3EQM), JAK2 (PDB: 5AEP), BCL-2 (PDB: 2O2F), and caspase3 (PDB: 1RE1) receptor proteins to obtain insights on anticancer activities of Mppth. The results displayed strong interactions with the receptors with binding energies -10.27, -7.40, -6.28, and -7.27 kcal/mol, respectively. From the docking results, the key binding interactions between the ligand and active site residues of the receptor were identified, which may provide important information for further research on the compound Mppth as anticancer agent. [Display omitted] [ABSTRACT FROM AUTHOR]

· A new compound 5(4-hydroxyphenyl)-2-(N-phenylamino)-1,3,4-oxadiazole (Hppo) is reported. • Mn(II) catalyzed cyclization of thiosemicarbazide to oxadiazole. • DFT, Single crystal structure and Hirshfeld surface analysis of Hppo. • In vitro cytotoxicity of Hppo against Dalton's lymphoma cells using MTT assay. • Molecular docking of Hppo with CYP-19, JAK2, BCL-2 & caspase3 receptors. [Display omitted] The syntheses and screening of novel synthetic molecules have gained attention as a potential therapeutic agent in the treatment of cancer. In the present study, a new compound 5(4-hydroxyphenyl)-2-(N-phenylamino)-1,3,4-oxadiazole (Hppo) has been synthesized and its anticancer activity is investigated against Dalton's lymphoma (DL) tumor cells derived from murine T-cell lymphoma. The Hppo has been characterized through IR, NMR, and single-crystal X-ray data. The structure of Hppo is stabilized via hydrogen bonding interactions and crystallizes in an orthorhombic system with space group P b c n. The fingerprint plots associated with Hirshfeld surface analysis indicate that there are different types of weak interactions viz. C-H···N, O-H···N and C-H···O. The DFT calculations are also performed to verify physiochemical properties of Hppo and the results obtained are in good agreement with the experimental results. The HOMO and LUMO energy gap of 7.344 eV for Hppo indicates good NLO properties. The cytotoxicity activity of Hppo is tested against Dalton's lymphoma cells using MTT assay which reveals that the compound showed admirable anticancer activity (IC 50 = 50 µg/mL), which is better than many previously reported compounds. The mechanism of action of Hppo is investigated by performing different biological studies and the results obtained reveal that Hppo acts through down-regulating mitochondrial membrane potential and up-regulating reactive oxygen species production. Molecular docking studies are also performed to obtain more insights on biological activities of Hppo and its mode of action against CYP-19 (PDB: 3EQM), JAK2 (PDB: 5AEP), BCL-2 (PDB: 2O2F), and caspase3 (PDB: 1RE1), and result displayed favorable binding interactions with binding energy -7.43, -7.96, -6.61, and -6.88 Kcal/mol. [ABSTRACT FROM AUTHOR]